112 related articles for article (PubMed ID: 14981943)
1. Analysis of Fas (Apo-1/CD95) expression in non-small cell lung cancer.
Esposito V; Baldi A; Liuzzi G; Tonini G; Vincenzi B; Persichetti P; Santini M; Ambrogi V; Mineo TC; Montesarchio V; Wolner E; Baldi F; Groeger AM
Anticancer Res; 2003; 23(6C):4901-5. PubMed ID: 14981943
[TBL] [Abstract][Full Text] [Related]
2. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
4. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
Volm M; Koomägi R
Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.
Liu H; Zhang T; Li X; Huang J; Wu B; Huang X; Zhou Y; Zhu J; Hou J
Cancer Sci; 2008 Nov; 99(11):2185-92. PubMed ID: 18823373
[TBL] [Abstract][Full Text] [Related]
7. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
9. Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA.
Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Dyla T; Jankowska R
In Vivo; 2009; 23(4):519-25. PubMed ID: 19567385
[TBL] [Abstract][Full Text] [Related]
10. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
11. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
[TBL] [Abstract][Full Text] [Related]
12. Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients.
Hastings RH; Laux AM; Casillas A; Xu R; Lukas Z; Ernstrom K; Deftos LJ
Clin Cancer Res; 2006 Jan; 12(2):499-506. PubMed ID: 16428492
[TBL] [Abstract][Full Text] [Related]
13. Maspin expression and its clinical significance in non-small cell lung cancer.
Nakagawa M; Katakura H; Adachi M; Takenaka K; Yanagihara K; Otake Y; Wada H; Tanaka F
Ann Surg Oncol; 2006 Nov; 13(11):1517-23. PubMed ID: 17009165
[TBL] [Abstract][Full Text] [Related]
14. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
Iwasaki T; Nakagawa K; Nakamura H; Takada Y; Matsui K; Kawahara K
Oncol Rep; 2005 Jun; 13(6):1075-80. PubMed ID: 15870924
[TBL] [Abstract][Full Text] [Related]
15. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung.
Kwon MS; Shin SH; Yim SH; Lee KY; Kang HM; Kim TM; Chung YJ
Lung Cancer; 2007 Jul; 57(1):46-53. PubMed ID: 17350713
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
[TBL] [Abstract][Full Text] [Related]
17. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
[TBL] [Abstract][Full Text] [Related]
18. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
Zhang Z; Ma J; Li N; Sun N; Wang C
Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
[TBL] [Abstract][Full Text] [Related]
19. [Expressions of Nm23, E-cadherin, and beta-catenin in non-small cell lung cancer and their correlations with metastasis and prognosis].
Tang XJ; Zhou QH; Zhang SF; Liu LX
Ai Zheng; 2005 May; 24(5):616-21. PubMed ID: 15890109
[TBL] [Abstract][Full Text] [Related]
20. The implications of proliferation and apoptosis for lung cancer metastasis.
Volm M; Koomagi R
Oncol Rep; 1999; 6(2):373-6. PubMed ID: 10023008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]